During the most recent 90-day period, previous to the date of this filing, there have been 14 insider transactions reported to the SEC for Fate Therapeutics. These transactions came from the activities of 5 individual insiders that resulted in a net disposition of 464,483 company shares. Relative to the preceding 90-day window of time, there was 1 transaction from 1 insider that resulted in the acquisition of 3,703,704 shares.
This is a lower level of transactions than the peer group average in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Within the peer group activity averaged 29.5 transactions per company, with company insiders acquiring on average 13,584 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1434316/000089924319002256/xslF345X03/doc4.xml
|Analysts Reduce Alleghany Corp's Q2, 2019, and 2020 ...|
|2019, and 2020 Estimates for United States Steel Low...|
|Extraction Oil & Gas' 2019, 2020, and Q2 Earnings Es...|
|Earnings Estimate for Viper Energy Partners in 2020 ...|
|Westlake Chemical's 2019, 2020, and Q2 Earnings Esti...|